BASF's Evonik Overture: A Bold Bid That Could Reshape German Chemicals
Published on 09/26/2026 at 13:21 | Editorial boerse-global.de
BASF has confirmed it is holding exploratory talks about a potential voluntary public takeover offer for Essen-based specialty chemicals group Evonik — a move that caught the market off guard and immediately weighed on its own shares. The Ludwigshafen giant said discussions are underway with both Evonik and the RAG Foundation, though it stressed that neither the progress nor the outcome of those talks is in any way assured. Evonik, for its part, acknowledged an unsolicited approach covering all of its shares but made clear that no negotiations are currently taking place.
Investors wasted little time rendering a verdict. BASF stock closed Friday down 2.6% at EUR 50.89, leaving the company with a market capitalization of EUR 45.03 billion. Reuters attributed the decline directly to speculation surrounding the potential acquisition.
A Timing Problem for a Company Mid-Transformation
What makes the overture so contentious is its timing. BASF is already deep into a sweeping overhaul of its corporate structure, and the prospect of simultaneously pursuing a multibillion-euro domestic acquisition raises immediate questions about capital allocation. Shareholders are now weighing whether such a step would strengthen the transformation or complicate reforms already in motion.
The company has no shortage of capital-intensive projects on its plate. It is evaluating an MDI investment in India, having already secured an industrial site in Dahej through a subsidiary. At the same time, it is shedding peripheral operations to unlock liquidity. Roughly two weeks ago, BASF enlisted four major banks — Citi, Deutsche Bank, Goldman Sachs and JPMorgan — to prepare the planned IPO of its Agricultural Solutions division, targeted for no earlier than mid-2027. Since that announcement, the stock has shed 3.0%.
That was preceded by the sale of the Coatings business to Carlyle more than a month ago, a divestment that generated roughly EUR 5.8 billion. The balancing act between divestments on one side and fresh takeover ambitions on the other is precisely what has market participants on edge.
Should investors sell immediately? Or is it worth buying BASF?
The RAG Foundation Holds the Keys
Whether BASF's gambit advances at all depends heavily on the RAG Foundation, Evonik's largest shareholder with a 44% stake — well above its long-term target of 25.1%. The Essen-based foundation uses dividend income to fund the perpetual liabilities of German hard-coal mining, spending EUR 309.3 million on those obligations in 2025. Evonik contributed EUR 252.3 million of that total in the same year.
The foundation faces a delicate calculation. Its future obligations carry a present value of EUR 31.4 billion, against provisions of just EUR 9.9 billion set aside so far. Evonik recently trimmed its dividend for 2025 from EUR 1.17 to EUR 1.00 per share and is targeting a payout ratio of 40% to 60% of adjusted group earnings from 2026 onward. With a return on capital of 6.1% against capital costs of 10%, the Essen group is itself under considerable restructuring pressure.
What a Combination Would Create — and Cost
Strategically, BASF is aiming squarely at the higher-margin specialty chemicals arena. Together, the two groups generated EUR 74 billion in revenue last year, with roughly EUR 60 billion coming from BASF and EUR 14.1 billion from Evonik. A merger would deliver greater market share and, critically, savings in administration as well as research and development.
The price tag, however, is substantial. Evonik's market value recently stood at around EUR 8.4 billion to EUR 9 billion, and a formal offer for all shares would likely require a significant premium — a transaction that would weigh heavily on BASF's balance sheet and curb room for future dividends or share buybacks. Integration risk compounds the challenge: merging two German chemical groups with complex integrated production sites and regulatory requirements would tie up management capacity for years.
In the optimistic scenario, BASF succeeds in complementing its portfolio with high-quality specialty chemicals without overpaying. Consolidation in the German chemicals sector could unlock meaningful savings in research, sales and administration, while a stronger specialty portfolio would reduce dependence on cyclical base chemicals. Some analysts remain constructive on the operational path: Bernstein Research raised its price target for BASF from EUR 62 to EUR 63 on Tuesday after talks with management, keeping an "Outperform" rating.
Antitrust Scrutiny and Evonik's Own Overhaul
Plenty of obstacles remain before any agreement could materialize. Beyond valuation and financing, antitrust authorities are expected to examine the combination of two German industry heavyweights closely. Both companies also operate in a demanding market environment marked by persistently high energy costs in Europe.
BASF at a turning point? This analysis reveals what investors need to know now.
Evonik is already in the midst of a comprehensive cost-cutting program. Roughly EUR 400 million in savings are targeted by the end of 2026, alongside the closure of its Hamburg and Bitterfeld sites by 2027 and the elimination of 3,200 jobs between 2027 and 2029.
Because Evonik has stated that no talks are currently underway, the risk of a protracted — or even hostile — takeover battle cannot be ruled out. Such a course could durably shake investor confidence in management's strategic reliability.
What Investors Are Watching Now
Attention now turns to the company's next moves. As long as the stock holds above its 200-day moving average of EUR 49.50, the broader trend remains intact. Should that technical support give way amid mounting takeover uncertainty, selling pressure could intensify in the near term.
Clarity on both the talks and the operating picture will arrive within weeks. On October 28, BASF will publish its written information for the third quarter of 2026 from 7:00 a.m. Until then, any comment from the management board on the Evonik plans is likely to set the direction of the share price.
Ad
BASF Stock: New Analysis - 26 September
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
